Celldex Scraps Atopic Dermatitis Program After Phase 2 Itch Data Miss
CLDX sits 23% above its 52-week low of $22.33 on light trading volume (0.2× avg).
Summary
Celldex is walking away from barzolvolimab in moderate-to-severe atopic dermatitis after the Phase 2 trial failed to beat placebo on itch. At Week 16 the 300 mg dose cut PP-NRS scores 29.2% and the 150 mg dose 16.2%, versus 19.5% for placebo — neither was statistically significant, and EASI and IGA secondary endpoints also failed to separate. Extending treatment to Week 32 added nothing. This follows the November 19 disclosure of the primary endpoint miss and is the second itch-program setback this year, after the July prurigo nodularis failure. The AD indication is now gone, but the core thesis rests on chronic spontaneous urticaria, where Phase 3 EMBARQ data read out positive in September and a BLA is planned for 2027; cold urticaria and symptomatic dermographism Phase 3 enrollment continues. Shares were down 0.25% premarket at $27.89, a muted reaction that suggests the miss was largely priced in.
At the time of this announcement, CLDX was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $22.33 to $45.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.